MabThera/Rituxan

Roche wins FDA breakthrough for Gazyva in lupus nephritis

Roche has been counting on a new class of medicines to help offset the  biosimilar onslaught on its ageing cancer blockbusters, including Herceptin and MabThera/Rituxan.

Genentech agrees trade secret theft settlement with Taiwan’s JHL

News of the spat emerged last year, with Genentech accusing JHL of stealing its confidential and proprietary information in order to guide the development of biosimilar versions of Rituxan (rituximab), Herceptin ... JHL has been developing biosimilars of

Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

its ‘big three’ antibiotic products – Rituxan, Herceptin and Avastin – which accounted for more than a third of sales last year.

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

The approval is the latest in a string of regulatory wins for Celgene, coming after approval of a combination of Revlimid (lenalidomide) and Roche’s Rituxan (rituximab) – known as the R2

Imbruvica gains expanded use in Europe

drug. The EC has approved the use of Imbruvica in combination with obinutuzumab (Gazyva, Roche) in adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and in combination with rituximab (Rituxan,

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]